BE Studies for OTC-drug [Regulatives / Guidelines]

posted by kumar – 2009-04-25 16:58 (6275 d 12:36 ago) – Posting: # 3613
Views: 6,046

Dear EM,

Thank you for the mail. This product is already authorised in EU & USA as an innovator. The drug is not locally acting. We have seen the SPC and is not of much help. As a generic product, we need to demonstrate its BE with the innovator. We do not have much bibliographic reference to ask for a waiver? We do not know in what way we can conduct clinical trials and BE Studies.
Need help.

Regards
Kumar

--
Edit: Full quote removed. Please delete anything from the text of the original poster which is not necessary in understanding your answer; see also this post! Helmut

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
306 visitors (0 registered, 306 guests [including 20 identified bots]).
Forum time: 05:34 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5